| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | WTAP |
| Uniprot No | Q15007 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-396aa |
| 氨基酸序列 | MTNEEPLPKKVRLSETDFKVMARDELILRWKQYEAYVQALEGKYTDLNSNDVTGLRESEEKLKQQQQESARRENILVMRLATKEQEMQECTTQIQYLKQVQQPSVAQLRSTMVDPAINLFFLKMKGELEQTKDKLEQAQNELSAWKFTPDSQTGKKLMAKCRMLIQENQELGRQLSQGRIAQLEAELALQKKYSEELKSSQDELNDFIIQLDEEVEGMQSTILVLQQQLKETRQQLAQYQQQQSQASAPSTSRTTASEPVEQSEATSKDCSRLTNGPSNGSSSRQRTSGSGFHREGNTTEDDFPSSPGNGNKSSNSSEERTGRGGSGYVNQLSAGYESVDSPTGSENSLTHQSNDTDSSHDPQEEKAVSGKGNRTVGSRHVQNGLDSSVNVQGSVL |
| 预测分子量 | 44.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于WTAP重组蛋白的3篇参考文献示例(部分信息为示例性总结，建议根据实际文献调整)：
---
1. **文献名称**: *Structural basis of WTAP recognition by the mRNA m6A methyltransferase complex*
**作者**: Smith A, et al.
**摘要**: 本研究通过重组表达WTAP蛋白及其互作蛋白METTL3/METTL14.解析了WTAP在m6A甲基转移酶复合体中的结构作用，揭示了其通过C端结构域稳定复合体组装的关键机制。
2. **文献名称**: *WTAP regulates post-transcriptional gene expression by interacting with the RNA exosome*
**作者**: Li Y, et al.
**摘要**: 利用重组WTAP蛋白进行体外RNA结合实验，证明WTAP通过与RNA外泌体相互作用调控特定mRNA的稳定性，影响细胞周期进程。
3. **文献名称**: *Recombinant WTAP protein exhibits phase separation in vitro and mediates m6A-dependent mRNA splicing*
**作者**: Wang X, et al.
**摘要**: 通过大肠杆菌系统表达纯化重组WTAP蛋白，发现其在体外可发生液-液相分离，并验证其通过m6A修饰参与前体mRNA剪接的分子机制。
---
**注意**：以上文献信息为示例，实际引用需根据具体研究内容检索PubMed、Web of Science等数据库获取。建议使用关键词“WTAP recombinant protein”、“WTAP purification”或“WTAP structure”查找相关文献。
WTAP (Wilms tumor 1-associated protein) is a conserved nuclear protein that plays a critical role in RNA metabolism and post-transcriptional gene regulation. Initially identified as a binding partner of the Wilms tumor 1 (WT1) protein, WTAP is a core component of the mammalian N6-methyladenosine (m6A) methyltransferase complex, which catalyzes the addition of m6A modifications to RNA. These modifications influence RNA splicing, stability, localization, and translation, thereby regulating diverse biological processes, including embryonic development, cell differentiation, and stress responses.
Recombinant WTAP proteins are engineered in vitro using expression systems like *E. coli* or mammalian cells to produce purified, functional WTAP for research. These proteins typically retain key functional domains, such as the WT1-binding region and motifs required for interaction with other m6A complex members (e.g., METTL3 and METTL14). Recombinant WTAP enables mechanistic studies of m6A-dependent RNA regulation and its role in diseases. For instance, dysregulation of WTAP has been linked to cancers (e.g., leukemia, solid tumors), neurological disorders, and developmental defects, making it a potential therapeutic target.
In experimental settings, recombinant WTAP is used to investigate its role in RNA methylation, protein-RNA interactions, and cellular pathways. It also serves as a tool for screening inhibitors or modulators of the m6A machinery. Quality-controlled batches are validated via SDS-PAGE, Western blot, and activity assays to ensure consistency. By providing a scalable and standardized source of WTAP, recombinant proteins accelerate research into epitranscriptomics and disease mechanisms, bridging gaps between molecular biology insights and clinical applications.
×
